Page 136 - 《中国药房》2025年17期

safety of oral semaglutide vs sitagliptin in a predomi‐ kidney disease in the FLOW trial[J]. Nat Med，2024，30
nantly Chinese population with type 2 diabetes uncon‐ （10）：2849-2856.
trolled with metformin：PIONEER 12，a double-blind， [43] APPERLOO E M，GORRIZ J L，SOLER M J，et al. Sema‐
phase Ⅲ a，randomised trial[J]. Diabetologia，2024，67 glutide in patients with overweight or obesity and chronic
（9）：1800-1816. kidney disease without diabetes：a randomized double-
[32] ARODA V R，ABERLE J，BARDTRUM L，et al. Efficacy blind placebo-controlled clinical trial[J]. Nat Med，2025，
and safety of once-daily oral semaglutide 25 mg and 50 31（1）：278-285.
mg compared with 14 mg in adults with type 2 diabetes [44] GARCÍA DE LUCAS M D， CABALLERO I，
（PIONEER PLUS）：a multicentre，randomised，phase 3b FERNÁNDEZ-GARCÍA J C，et al. Influence of chronic
trial[J]. Lancet，2023，402（10403）：693-704. kidney disease and its severity on the efficacy of semaglu‐
[33] PRATLEY R E，ARODA V R，LINGVAY I，et al. Sema‐ tide in type 2 diabetes patients：a multicenter real-world
glutide versus dulaglutide once weekly in patients with study[J]. Front Endocrinol （Lausanne） ，2023，14：
type 2 diabetes （SUSTAIN 7）：a randomised，open-label， 1240279.
phase 3b trial[J]. Lancet Diabetes Endocrinol，2018，6（4）： [45] COLHOUN H M，LINGVAY I，BROWN P M，et al. Long-
275-286. term kidney outcomes of semaglutide in obesity and car‐
[34] ARODA V R，ERHAN U，JELNES P，et al. Safety and diovascular disease in the SELECT trial[J]. Nat Med，
tolerability of semaglutide across the SUSTAIN and 2024，30（7）：2058-2066.
PIONEER phase Ⅲa clinical trial programmes[J]. Diabe‐ [46] ANDERER S. FDA approves semaglutide to reduce risk
tes Obes Metab，2023，25（5）：1385-1397. of kidney disease progression[J]. JAMA，2025，333（13）：
[35] GARG S K，KAUR G，HAIDER Z，et al. Efficacy of 1109.
semaglutide in overweight and obese patients with type 1 [47] ESCOBAR-MORREALE H F. Polycystic ovary syn‐
diabetes[J]. Diabetes Technol Ther，2024，26（3）：184-189. drome：definition，aetiology，diagnosis and treatment[J].
[36] LINGVAY I，DEANFIELD J，KAHN S E，et al. Semaglu‐ Nat Rev Endocrinol，2018，14（5）：270-284.
tide and cardiovascular outcomes by baseline HbA1c and [48] JENSTERLE M，FERJAN S，LEŽAIČ L K，et al. Sema‐
change in HbA1c in people with overweight or obesity but glutide delays 4-hour gastric emptying in women with
without diabetes in SELECT[J]. Diabetes Care，2024，47 polycystic ovary syndrome and obesity[J]. Diabetes Obes
（8）：1360-1369. Metab，2023，25（4）：975-984.
[37] KAHN S E，DEANFIELD J E，JEPPESEN O K，et al. Ef‐ [49] ZHU K，KAKKAR R，CHAHAL D，et al. Efficacy and
fect of semaglutide on regression and progression of gly‐ safety of semaglutide in non-alcoholic fatty liver disease
cemia in people with overweight or obesity but without [J]. World J Gastroenterol，2023，29（37）：5327-5338.
diabetes in the SELECT trial[J]. Diabetes Care，2024，47 [50] 牟钰钦，罗易，王思琪，等. 司美格鲁肽药物不良反应的
（8）：1350-1359. 临床表现及相关影响因素分析[J]. 保健医学研究与实
[38] IRFAN H. Obesity，cardiovascular disease，and the pro- 践，2024，21（6）：105-109.
mising role of semaglutide：insights from the SELECT [51] 孙如男，仓代晓，全香花，等. 司美格鲁肽致药品不良反
trial[J]. Curr Probl Cardiol，2024，49（1 Pt A）：102060. 应文献分析[J]. 中国药房，2024，35（18）：2266-2271.
[39] SOLOMON S D，OSTROMINSKI J W，WANG X W， [52] BROWN C. High price and demand for semaglutide
et al. Effect of semaglutide on cardiac structure and func‐ means lack of access for US patients[J]. BMJ，2023，382：
tion in patients with obesity-related heart failure[J]. J Am 1863.
Coll Cardiol，2024，84（17）：1587-1602. [53] BUSE J B，WEXLER D J，TSAPAS A，et al. 2019 update
[40] HUSAIN M，CONSOLI A，DE REMIGIS A，et al. Sema‐ to：management of hyperglycemia in type 2 diabetes，
glutide reduces cardiovascular events regardless of metfor‐ 2018. A consensus report by the American Diabetes Asso‐
min use：a post hoc subgroup analysis of SUSTAIN 6 and ciation （ADA） and the European Association for the
PIONEER 6[J]. Cardiovasc Diabetol，2022，21（1）：64. Study of Diabetes （EASD） [J]. Diabetes Care，2020，43
[41] JIANG Z M，WANG Y，ZHAO X，et al. Obesity and （2）：487-493.
chronic kidney disease[J]. Am J Physiol Endocrinol [54] FEZZA R，RAINS B，FEZZA T，et al. Emerging anesthe‐
Metab，2023，324（1）：E24-E41. sia risks with semaglutide[J]. Plast Reconstr Surg Glob
[42] MANN J F E，ROSSING P，BAKRIS G，et al. Effects of Open，2023，11（11）：e5427.
semaglutide with and without concomitant SGLT2 inhibi‐ （收稿日期：2025-04-18 修回日期：2025-08-05）
tor use in participants with type 2 diabetes and chronic （编辑：唐晓莲）

· 2210 · China Pharmacy 2025 Vol. 36 No. 17 中国药房 2025年第36卷第17期